DDrare: Database of Drug Development for Rare Diseases

Other: other biologic agents (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease [ 2,209 clinical trials, 1,276 drugs, (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02674308 (ClinicalTrials.gov)	March 31, 2015	29/1/2016	Entyvio (Vedolizumab) Long Term Safety Study	Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease	Ulcerative Colitis and Crohn's Disease	Drug: Vedolizumab;Other: Other Biologic Agents	Takeda	NULL	Active, not recruiting	18 Years	N/A	All	5302		United States;Austria;Belgium;Canada;Croatia;Denmark;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom

97. Ulcerative colitis [ 2,269 clinical trials, 1,331 drugs, (DrugBank: 241 drugs), 114 drug target genes, 181 drug target pathways]

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,269 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02674308 (ClinicalTrials.gov)	March 31, 2015	29/1/2016	Entyvio (Vedolizumab) Long Term Safety Study	Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease	Ulcerative Colitis and Crohn's Disease	Drug: Vedolizumab;Other: Other Biologic Agents	Takeda	NULL	Active, not recruiting	18 Years	N/A	All	5302		United States;Austria;Belgium;Canada;Croatia;Denmark;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom